R-107(Radikal Therapeutics)

N/A

Report date: 2025/08/19 11:14:34
NME

Base Information

Drug NameR-107(Radikal Therapeutics)
Drug Alias NameR-107
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell death stimulantsAndrogen Receptor antagonistsNitric oxide donors +[6] 
TargetsReactive oxygen speciesAndrogen ReceptorGuanylate cyclase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Acute Lung InjuryPulmonary Arterial Hypertension +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRadikal Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesRadikal Therapeutics
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Acute Lung InjuryPulmonary Arterial Hypertension +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A